BBC - ETF AI Analysis
Top Page
Virtus LifeSci Biotech Clinical Trials ETF (BBC)
Rating:43Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and over the past few months, indicating positive momentum in its clinical biotech focus.
Healthy Top Holdings Performance
Most of the top 10 holdings have delivered strong year-to-date returns, helping support the fund’s overall results.
Focused Exposure to Health Care Innovation
With most assets in health care and clinical biotech companies, the fund gives targeted access to a sector driven by new drug and treatment development.
Negative Factors
High Expense Ratio
The fund’s fees are relatively high compared with many broad-market ETFs, which can reduce investors’ net returns over time.
Sector Concentration Risk
Heavy exposure to health care and biotech means the ETF is more vulnerable to downturns or setbacks in this single industry.
Limited Geographic Diversification
With almost all holdings in U.S. companies, the fund offers little global diversification and is closely tied to the U.S. market and regulatory environment.
BBC vs. SPDR S&P 500 ETF (SPY)
AUM47.92M
RegionNorth America
Expense Ratio0.65%
Beta1.37
IssuerVirtus
Inception DateDec 16, 2014
Dividend Yield1.3%
Asset ClassEquity
Index TrackedLifeSci Biotechnology Clinical Trials Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume32,858
30 Day Avg. Volume27,633
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
102.97Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering131
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BBC Summary
BBC, the Virtus LifeSci Biotech Clinical Trials ETF, follows the LifeSci Biotechnology Clinical Trials Index and focuses on U.S. healthcare and life sciences companies running drug and treatment trials. It holds many smaller, research-driven biotech firms such as Xencor and RegenXBio, giving investors a way to bet on future medical breakthroughs in one fund instead of picking individual stocks. Someone might invest in BBC for growth potential and diversification within cutting-edge biotech. However, this ETF is concentrated in early-stage biotech companies, so its price can be very volatile and may go up and down sharply with news about clinical trial results.
How much will it cost me?The Virtus LifeSci Biotech Clinical Trials ETF (Ticker: BBC) has an expense ratio of 0.79%, which means you’ll pay $7.90 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on a specialized niche in the biotechnology sector that requires more research and expertise.
What would affect this ETF?The Virtus LifeSci Biotech Clinical Trials ETF could benefit from advancements in biotechnology and medical research, as well as increased funding for healthcare innovation in the U.S., where it is primarily focused. However, it may face challenges from regulatory hurdles, high costs associated with clinical trials, and potential setbacks in drug approvals, which could negatively impact the performance of its top holdings. Economic conditions, such as changes in interest rates or reduced investor appetite for high-risk sectors, could also influence the ETF's future performance.
BBC Top 10 Holdings
BBC is a pure play on U.S. clinical-stage biotech, so a handful of rising trial names are steering the ship. Definium Therapeutics, Apogee Therapeutics, and Biohaven have been climbing on optimism around their pipelines, giving the fund some welcome lift. 4D Molecular Therapeutics and MBX Biosciences are also contributing steady to rising momentum. On the flip side, uniQure’s mixed trajectory and Viking Therapeutics losing a bit of steam are holding back returns. With nearly all its weight in health care, this ETF lives and dies by small, volatile biotech stories.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| First Tracks Biotherapeutics Inc | 1.35% | $658.46K | $1.30B | ― | ― | |
| Monopar Therapeutics Inc | 1.21% | $590.56K | $760.81M | 151.15% | 48 Neutral | |
| Definium Therapeutics | 1.16% | $566.11K | $5.98B | 367.63% | 40 Neutral | |
| Atai Beckley N.V. | 1.16% | $565.73K | $2.64B | 102.12% | 47 Neutral | |
| MBX Biosciences, Inc. | 1.08% | $527.69K | $2.87B | 340.64% | 38 Underperform | |
| Xencor | 1.05% | $515.50K | $1.52B | 122.28% | 59 Neutral | |
| SELLAS Life Sciences Group | 1.05% | $512.07K | $2.40B | 556.52% | 43 Neutral | |
| Zenas BioPharma, Inc. | 1.04% | $507.95K | $2.04B | 107.17% | 61 Neutral | |
| Damora Therapeutics | 1.01% | $493.43K | $2.03B | 806.32% | 29 Underperform | |
| RegenXBio | 0.99% | $482.57K | $534.55M | 20.65% | 54 Neutral |
BBC Technical Analysis
Neutral
―
Price Trends
46.80
Positive
45.00
Positive
40.77
Positive
Market Momentum
1.00
Positive
51.56
Neutral
36.67
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBC, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 51.85, equal to the 50-day MA of 46.80, and equal to the 200-day MA of 40.77, indicating a neutral trend. The MACD of 1.00 indicates Positive momentum. The RSI at 51.56 is Neutral, neither overbought nor oversold. The STOCH value of 36.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BBC.
BBC Peer Comparison
Comparison Results
Performance Comparison
BBC
Virtus LifeSci Biotech Clinical Trials ETF
50.31
28.40
129.62%
MILN
Global X Millennial Consumer ETF
―
―
―
BBP
Virtus LifeSci Biotech Products ETF
―
―
―
IBBQ
Invesco Nasdaq Biotechnology ETF
―
―
―
FTXH
First Trust Nasdaq Pharmaceuticals ETF
―
―
―
ASD
Defiance Autism Impact ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents